Federal GLP-1 expansion programs reproduce the access hierarchy at the program design level, not just through market dynamics

The Medicare GLP-1 Bridge program demonstrates that the GLP-1 access inversion operates at the program design level, not just the market level. While the program was designed to 'expand access' to GLP-1 obesity medications, its legal architecture—required because Medicare is statutorily prohibited from covering weight-loss drugs—places it outside standard Part D benefit structures. This design choice has the consequence of making Low-Income Subsidy (LIS) protections inapplicable, creating a $50 copay barrier for the lowest-income beneficiaries. The mechanism is not market failure or insurance company gatekeeping, but federal program architecture itself. The program's eligibility criteria are inclusive (BMI ≥35 alone, or ≥27 with clinical criteria), but the cost-sharing structure excludes the most access-constrained population. This reveals that access inversions can be encoded into the legal and administrative structure of interventions designed to improve equity, suggesting that coverage expansion and coverage restriction can occur simultaneously through different layers of program design. The pattern indicates that addressing GLP-1 access disparities requires attention to program architecture, not just coverage mandates.

Supporting Evidence

Source: KFF 2025 poll demographic breakdown

Age 65+ adults show only 9% GLP-1 usage compared to 22% for ages 50-64, directly reflecting Medicare's statutory exclusion of weight-loss drugs. This creates a sharp discontinuity at the Medicare eligibility threshold despite this population having the highest obesity burden and worst health outcomes. The demographic pattern confirms that structural coverage exclusions, not clinical need, determine access.

Supporting Evidence

Source: National Law Review, FDA April 1 2026 clarification

Despite FDA's February 2026 announcement of 'decisive enforcement action' against non-approved compounded GLP-1s, compounded semaglutide remains available via 503A pharmacies at $99/month as of April 2026. However, the 4 prescription/month safe harbor limit means this pathway is structurally unavailable at population scale (estimated 100K+ patients cannot be served through 503A). State regulatory responses have created a patchwork: some states enacted protective legislation for patient access while others imposed stricter controls. The access hierarchy persists with the affordable channel legally precarious and architecturally constrained.